Ormeloxifene nanotherapy for cervical cancer treatment

Neeraj Chauhan1,2, Diane M Maher3, Bilal B Hafeez1,2, Hassan Mandil1, Man M Singh4, Murali M Yallapu1,2, Meena Jaggi1,2, Subhash C Chauhan1,2 1Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; 2Department of Immunology and Microbiology, Sch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chauhan N, Maher DM, Hafeez BB, Mandil H, Singh MM, Yallapu MM, Jaggi M, Chauhan SC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	CxCa ORM PLGA Nanoformulation Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5fc2ac6eae07492bbae82d4f6e4eeb44
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5fc2ac6eae07492bbae82d4f6e4eeb44
record_format	dspace
spelling	oai:doaj.org-article:5fc2ac6eae07492bbae82d4f6e4eeb442021-12-02T08:16:37ZOrmeloxifene nanotherapy for cervical cancer treatment1178-2013https://doaj.org/article/5fc2ac6eae07492bbae82d4f6e4eeb442019-09-01T00:00:00Zhttps://www.dovepress.com/ormeloxifene-nanotherapy-for-cervical-cancer-treatment-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Neeraj Chauhan1,2, Diane M Maher3, Bilal B Hafeez1,2, Hassan Mandil1, Man M Singh4, Murali M Yallapu1,2, Meena Jaggi1,2, Subhash C Chauhan1,2 1Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; 2Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA; 3Sanford Research Center, USD, Sioux Falls, SD 57104, USA; 4Research and Development, Saraswati Dental College, Lucknow, Uttar Pradesh, IndiaCorrespondence: Meena Jaggi; Subhash C ChauhanDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USATel +1 956 296 1926; +1 956 296 5000Email meena.jaggi@utrgv.edu; subhash.chauhan@utrgv.eduBackground: Cervical cancer (CxCa) ranks as the fourth most prevalent women-related cancer worldwide. Therefore, there is a crucial need to develop newer treatment modalities. Ormeloxifene (ORM) is a non-steroidal, selective estrogen receptor modulator (SERM) that is used as an oral contraceptive in humans. Recent investigations suggest that ORM exhibits potent anti-cancer activity against various types of cancers. Nanoparticulates offer targeted delivery of anti-cancer drugs with minimal toxicity and promise newer approaches for cancer diagnosis and treatment. Therefore, the nanotherapy approach is superior compared to traditional chemotherapy, which is not site-specific and is often associated with various side effects.Methods: Pursuing this novel nanotherapy approach, our lab has recently developed ORM-loaded poly [lactic-co-glycolic acid] (PLGA), an FDA-approved biodegradable polymer, nanoparticles to achieve targeted drug delivery and improved bioavailability. Our optimized PLGA-ORM nanoformulation showed improved internalization in both dose- and energy-dependent manners, through endocytosis-mediated pathways in both Caski and SiHa cell lines. Additionally, we employed MTS and colony forming assays to determine the short- and long-term effects of PLGA-ORM on these cells.Results: Our results showed that this formulation demonstrated improved inhibition of cellular proliferation and clonogenic potential compared to free ORM. Furthermore, the PLGA-ORM nanoformulation exhibited superior anti-tumor activities in an orthotopic cervical cancer mouse model than free ORM.Conclusion: Collectively, our findings suggest that our novel nanoformulation has great potential for repurposing the drug and becoming a novel modality for CxCa management.Keywords: CxCa, ORM, PLGA, nanoformulationChauhan NMaher DMHafeez BBMandil HSingh MMYallapu MMJaggi MChauhan SCDove Medical PressarticleCxCaORMPLGANanoformulationMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 7107-7121 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	CxCa ORM PLGA Nanoformulation Medicine (General) R5-920
spellingShingle	CxCa ORM PLGA Nanoformulation Medicine (General) R5-920 Chauhan N Maher DM Hafeez BB Mandil H Singh MM Yallapu MM Jaggi M Chauhan SC Ormeloxifene nanotherapy for cervical cancer treatment
description	Neeraj Chauhan1,2, Diane M Maher3, Bilal B Hafeez1,2, Hassan Mandil1, Man M Singh4, Murali M Yallapu1,2, Meena Jaggi1,2, Subhash C Chauhan1,2 1Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; 2Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA; 3Sanford Research Center, USD, Sioux Falls, SD 57104, USA; 4Research and Development, Saraswati Dental College, Lucknow, Uttar Pradesh, IndiaCorrespondence: Meena Jaggi; Subhash C ChauhanDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USATel +1 956 296 1926; +1 956 296 5000Email meena.jaggi@utrgv.edu; subhash.chauhan@utrgv.eduBackground: Cervical cancer (CxCa) ranks as the fourth most prevalent women-related cancer worldwide. Therefore, there is a crucial need to develop newer treatment modalities. Ormeloxifene (ORM) is a non-steroidal, selective estrogen receptor modulator (SERM) that is used as an oral contraceptive in humans. Recent investigations suggest that ORM exhibits potent anti-cancer activity against various types of cancers. Nanoparticulates offer targeted delivery of anti-cancer drugs with minimal toxicity and promise newer approaches for cancer diagnosis and treatment. Therefore, the nanotherapy approach is superior compared to traditional chemotherapy, which is not site-specific and is often associated with various side effects.Methods: Pursuing this novel nanotherapy approach, our lab has recently developed ORM-loaded poly [lactic-co-glycolic acid] (PLGA), an FDA-approved biodegradable polymer, nanoparticles to achieve targeted drug delivery and improved bioavailability. Our optimized PLGA-ORM nanoformulation showed improved internalization in both dose- and energy-dependent manners, through endocytosis-mediated pathways in both Caski and SiHa cell lines. Additionally, we employed MTS and colony forming assays to determine the short- and long-term effects of PLGA-ORM on these cells.Results: Our results showed that this formulation demonstrated improved inhibition of cellular proliferation and clonogenic potential compared to free ORM. Furthermore, the PLGA-ORM nanoformulation exhibited superior anti-tumor activities in an orthotopic cervical cancer mouse model than free ORM.Conclusion: Collectively, our findings suggest that our novel nanoformulation has great potential for repurposing the drug and becoming a novel modality for CxCa management.Keywords: CxCa, ORM, PLGA, nanoformulation
format	article
author	Chauhan N Maher DM Hafeez BB Mandil H Singh MM Yallapu MM Jaggi M Chauhan SC
author_facet	Chauhan N Maher DM Hafeez BB Mandil H Singh MM Yallapu MM Jaggi M Chauhan SC
author_sort	Chauhan N
title	Ormeloxifene nanotherapy for cervical cancer treatment
title_short	Ormeloxifene nanotherapy for cervical cancer treatment
title_full	Ormeloxifene nanotherapy for cervical cancer treatment
title_fullStr	Ormeloxifene nanotherapy for cervical cancer treatment
title_full_unstemmed	Ormeloxifene nanotherapy for cervical cancer treatment
title_sort	ormeloxifene nanotherapy for cervical cancer treatment
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/5fc2ac6eae07492bbae82d4f6e4eeb44
work_keys_str_mv	AT chauhann ormeloxifenenanotherapyforcervicalcancertreatment AT maherdm ormeloxifenenanotherapyforcervicalcancertreatment AT hafeezbb ormeloxifenenanotherapyforcervicalcancertreatment AT mandilh ormeloxifenenanotherapyforcervicalcancertreatment AT singhmm ormeloxifenenanotherapyforcervicalcancertreatment AT yallapumm ormeloxifenenanotherapyforcervicalcancertreatment AT jaggim ormeloxifenenanotherapyforcervicalcancertreatment AT chauhansc ormeloxifenenanotherapyforcervicalcancertreatment
_version_	1718398602108207104

Ormeloxifene nanotherapy for cervical cancer treatment

Ejemplares similares